美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.69

-0.4365-1.24%

盤後：34.710.0207+0.06%19:30 EDT

成交量：2.55萬

成交額：88.53萬

市值：9,643.63萬

市盈率：- -

高：35.13

開：35.13

低：34.63

收：35.13

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：1.14

換手率：0.92%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

糖尿病GLP-1創新藥獲中國藥學會科技獎一等獎，已啓動肥胖治療臨床試驗

藥捷安康-B(02617.HK)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥

藥捷安康-B(02617)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥

開源證券：原料藥板塊業績增速企穩回升創新藥及CDMO轉型公司進入兑現期

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/IBBQ"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.6893,"timestamp":1789761600000,"preClose":35.1258,"halted":0,"volume":25488,"hourTrading":{"tag":"盘后","latestPrice":34.71,"preClose":34.6893,"latestTime":"19:30 EDT","volume":16,"amount":555.1565,"timestamp":1789774205753,"change":0.0207,"changeRate":0.000597,"amplitude":0},"delay":0,"changeRate":-0.012426763233862154,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"休市中","change":-0.4365,"latestTime":"09-18 16:00:00 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":885294.380736,"amplitude":0.014246,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":35.11978,"aum":97633023.51978,"dividendRate":0.007406,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.71,"preClose":34.6893,"latestTime":"19:30 EDT","volume":16,"amount":555.1565,"timestamp":1789774205753,"change":0.0207,"changeRate":0.000597,"amplitude":0},"volumeRatio":1.1394951737825971,"impliedVol":0.0457,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1394951737825971,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.6893,"eps":0,"divideRate":0.007406,"volume":25488,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"IBBQ","amount":0.23037,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668997758","title":"糖尿病GLP-1創新藥獲中國藥學會科技獎一等獎，已啓動肥胖治療臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2668997758","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668997758?lang=zh_tw&edition=fundamental","pubTime":"2026-09-19 14:05","pubTimestamp":1789797920,"startTime":"0","endTime":"0","summary":"第21届中国药学会科学技术奖近日揭晓，上海银诺医药技术有限公司完成的“亚洲首款人源长效GLP-1受体激动剂依苏帕格鲁肽α研发及应用”项目荣获中国药学会科学技术奖一等奖。依苏帕格鲁肽α已在中国内地和澳门获批上市，用于成人2型糖尿病治疗，并纳入国家医保目录。在成人超重和肥胖、青少年肥胖症治疗领域，银诺医药正在我国和澳大利亚开展临床试验，有望为这款创新药增加新的适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609193879212162.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609193879212162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","BK1574","MEDX","06978","159992","LNGR","MDTX","PSYK","BMED","JDOC","BK1161","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940687","title":"藥捷安康-B(02617.HK)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940687?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 18:54","pubTimestamp":1789728877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","PSYK","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668894069","title":"藥捷安康-B(02617)：替恩戈替尼聯合新型內分泌治療用於經治後進展的轉移性去勢抵抗性前列腺癌中國II期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2668894069","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668894069?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 18:54","pubTimestamp":1789728877,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，本公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验，于近日完成首例患者给药。其中新型内分泌治疗药物虽可显著延长患者生存期，为当前mCRPC一线核心治疗方案，但绝大多数患者最终会发生获得性耐药。替恩戈替尼单一疗法已在既往接受过多线治疗的mCRPC患者显出令人鼓舞的抗肿瘤疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBJ","MDTX","02617","BK1161","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668965944","title":"開源證券：原料藥板塊業績增速企穩回升 創新藥及CDMO轉型公司進入兑現期","url":"https://stock-news.laohu8.com/highlight/detail?id=2668965944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668965944?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 17:28","pubTimestamp":1789723709,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开源证券发布研报称，国内原料药行业逐渐企稳回升，部分公司积极布局创新药赛道，持续拓展公司天花板，有望进入收获期。开源证券主要观点如下：原料药板块：业绩增速企稳回升，创新药及CDMO转型公司进入兑现期随着原料药行业去库存逐步完成、落后产能加速出清，板块基本面开始出现改善迹象，营收及净利润已逐步触底回升，毛利率相对稳定，估值水平呈现修复趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","IBBQ","06978","CDMO","BK1161","MEDX","159992","161027","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":54,"pageCount":1,"totalSize":213,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IBBQ\",params:#limit:6,delay:false,,,undefined,":[]}}